ArticleCell cycle (Georgetown, Tex.)2020
The Lnc LINC00461/miR-30a-5p facilitates progression and malignancy in non-small cell lung cancer via regulating ZEB2.
Article in Cell cycle (Georgetown, Tex.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- LINC01082 Inhibits Non-Small Cell Lung Cancer by Targeting the miR-543/TNRC6A Axis.Biochemical genetics · 2023Article
- Positive feedback regulation of lncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer.Cancer science · 2022Article
- Long noncoding RNA RP11-909N17.2 presages a poor prognosis of non-small cell lung cancer.Cancer biomarkers : section A of Disease markers · 2022Article
- LINC00961 functions as an anti-oncogene in non-small cell lung carcinoma by regulation of miR-3127.American journal of translational research · 2022Article
- LINC-DUBR Suppresses Malignant Progression of Ovarian Cancer by Downregulating miR-107 to Induce SMAC Expression.Journal of healthcare engineering · 2022Article
- Article
- Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer.Advanced drug delivery reviews · 2021Review
- mFrontiers in oncology · 2021Article
- ANLN Regulated by miR-30a-5p Mediates Malignant Progression of Lung Adenocarcinoma.Computational and mathematical methods in medicine · 2021Article
- MIR100HG Regulates CALD1 Gene Expression by Targeting miR-142-5p to Affect the Progression of Bladder Cancer CellsFrontiers in molecular biosciences · 2021Article
Corrections and comments
- Retraction · 2023-02-02Concerns/Issues about Data · Original Data and/or Images not Provided and/or not Available ·
- Retracted
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies have found that Lnc LINC00461 is an important regulator of cancer. However, the function of Lnc LINC00461 in NSCLC is not known. Therefore, this experimental design was based on Lnc LINC00461 to explore the pathogenesis of Non-small cell lung cancer (NSCLC). RT-qPCR was used to detect the expression of lnc LINC00461 and miR-30a-5p in NSCLC. The CCK-8 method and Transwell assay were used to detect the effects of lnc LINC00461 and miR-30a-5p on proliferation, migration in NSCLC. Target gene prediction and screening, luciferase reporter assays were used to validate downstream target genes of lnc LINC00461 and miR-30a-5p. The protein expression of ZEB2 was detected by Western blot. The tumor changes in mice were detected by in vivo experiments. Lnc LINC00461 was significantly elevated in NSCLC. Lnc LINC00461 knockdown significantly inhibited proliferation and migration in NSCLC. miR-30a-5p was a direct target of lnc LINC00461 and miR-30a-5p was significantly reduced in NSCLC. shLINC00461 and miR-30a-5p inhibitor partially eliminated the effect of shLINC00461 on cell proliferation. And lnc LINC00461 was negatively correlated with miR-30a-5p expression. ZEB2 was a direct target of miR-30a-5p, and miR-30a-5p mimic and sh lnc LINC00461 significantly reduced ZEB2 expression levels. Finally, In vivo, lnc LINC00461 promoted tumor growth by modulating the miR-30a-5p / ZEB2 axis. In conclusion, LncLINC00461 promoted the progression of NSCLC by the miR-30a-5p / ZEB2 axis, and lnc LINC00461 may be a potential therapeutic target for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.